Last reviewed · How we verify
NCT05890092: VdiN
Vulvar Disease in Nigeria Observational Study
trial testing Observation in Vulvar Diseases in 1,000 participants. Currently enrolling.
2 May 2026
Quick facts
| Lead sponsor | KDRS ltd |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 3 May 2023 |
| Primary completion | 2 May 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Observation
Conditions studied
- Vulvar Diseases — all drugs for Vulvar Diseases →
- Vulvar Atrophy — all drugs for Vulvar Atrophy →
- Dermatoses — all drugs for Dermatoses →
Sponsor
KDRS ltd
Who can join
Adults 10 to 90, female only, with Vulvar Diseases or Vulvar Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Vulvar disease in Nigeria A look at awareness within patients and health practitioners, self-reported and actual prevalence within communities in Nigeria
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05890092
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observation
Trials testing the same drug.
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
- NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
Other recruiting trials for Vulvar Diseases
Currently open trials in the same condition.
- NCT06495554 — Danish Vulva Cancer Recurrence Study · NA · recruiting
- NCT06070454 — Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant L · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05890092 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by KDRS ltd
- Last refreshed: 6 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05890092.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing